Stock Track | Repligen Soars 5.74% Intraday on Strong Q1 Results, Beats Estimates and Raises Guidance

Stock Track
05/05

Repligen Corporation's stock surged 5.74% during intraday trading on Tuesday, following the release of its first quarter 2026 financial results.

The bioprocessing technology company reported Q1 revenue of $194 million, a 15% year-over-year increase that slightly exceeded analyst expectations. More notably, adjusted earnings per share rose 23% to $0.48, significantly beating the consensus estimate of $0.39. The strong performance was driven by 11% organic revenue growth and 160 basis points of adjusted operating margin expansion.

Management reinforced investor confidence by reiterating full-year organic revenue growth guidance of 9%-13% while raising adjusted EPS guidance to $1.97-$2.05. The company also highlighted strategic progress including the divestiture of its non-core Polymem filtration business and a new OEM partnership in China designed to increase competitiveness and access to local manufacturing.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10